A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis
NCT00720382
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
703
Enrollment
INDUSTRY
Sponsor class
Conditions
Perennial Allergic Rhinitis
Interventions
DRUG:
0.15% azelastine hydrochloride
DRUG:
Mometasone furoate
Sponsor
Meda Pharmaceuticals